NAD 299 hydrochloride
Cat. No. 3282
Chemical Name: (3R)-3-(Dicyclobutylamino)-8-fluoro
Biological ActivitySelective, high affinity 5-HT1A receptor antagonist (Ki = 0.6 nM in vitro). Enhances the action of selective 5-HT reuptake inhibitors and reverses citalopram-induced (Cat. No. 1427) inhibition of serotonergic cell firing.
Licensing InformationSold for research purposes under agreement from AstraZeneca
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Arborelius et al (1999) The 5-HT1A receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing. Eur.J.Pharmacol. 382 133. PMID: 10528148.
Larsson et al (1998) Differential regional antagonism of 8-OH-DPAT-induced decrease in serotonin synthesis by two 5-HT1A receptor antagonists. Eur.J.Pharmacol. 346 209. PMID: 9652362.
Johansson et al (1997) The pharmacological characterization of a novel selective 5-hydroxytryptamine-1A receptor antagonist, NAD-299. J.Pharamacol.Exp.Ther. 283 216.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses NAD 299 hydrochloride from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: NAD 299 hydrochloride, supplier, AstraZeneca, 5-HT1A, serotonin, 5-HT, receptor, antagonists, NAD299, Tocris Bioscience, 5-HT1A Receptor Antagonist products
Find multiple products by catalog number
November 12 - 16, 2016
San Diego, CA, USA